Biondo Investment Advisors LLC Trims Stake in AbbVie Inc. $ABBV

Biondo Investment Advisors LLC decreased its position in shares of AbbVie Inc. (NYSE:ABBV) by 3.0% during the fourth quarter, Holdings Channel reports. The fund owned 76,248 shares of the company’s stock after selling 2,336 shares during the period. AbbVie makes up about 2.1% of Biondo Investment Advisors LLC’s holdings, making the stock its 11th biggest holding. Biondo Investment Advisors LLC’s holdings in AbbVie were worth $17,422,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the company. Bank of Jackson Hole Trust grew its holdings in shares of AbbVie by 0.6% during the 4th quarter. Bank of Jackson Hole Trust now owns 7,213 shares of the company’s stock worth $1,648,000 after acquiring an additional 44 shares during the period. Eclectic Associates Inc. ADV grew its holdings in shares of AbbVie by 0.8% during the 4th quarter. Eclectic Associates Inc. ADV now owns 5,852 shares of the company’s stock worth $1,337,000 after acquiring an additional 45 shares during the period. Weil Company Inc. grew its holdings in shares of AbbVie by 2.3% during the 3rd quarter. Weil Company Inc. now owns 2,026 shares of the company’s stock worth $469,000 after acquiring an additional 46 shares during the period. Hardin Capital Partners LLC grew its holdings in shares of AbbVie by 1.4% during the 4th quarter. Hardin Capital Partners LLC now owns 3,321 shares of the company’s stock worth $759,000 after acquiring an additional 46 shares during the period. Finally, Dogwood Wealth Management LLC grew its holdings in shares of AbbVie by 10.8% during the 4th quarter. Dogwood Wealth Management LLC now owns 473 shares of the company’s stock worth $108,000 after acquiring an additional 46 shares during the period. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have weighed in on the company. Piper Sandler upped their target price on AbbVie from $294.00 to $298.00 and gave the stock an “overweight” rating in a report on Thursday, May 14th. Guggenheim reiterated a “buy” rating and set a $249.00 target price on shares of AbbVie in a report on Friday, May 1st. Cantor Fitzgerald reiterated an “overweight” rating and set a $240.00 target price on shares of AbbVie in a report on Thursday, April 30th. DZ Bank upgraded AbbVie from a “hold” rating to a “strong-buy” rating in a report on Thursday, April 30th. Finally, Evercore set a $235.00 price target on AbbVie in a research report on Friday, May 15th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $253.43.

AbbVie Stock Up 1.2%

Shares of ABBV opened at $227.54 on Friday. The stock has a market cap of $402.02 billion, a P/E ratio of 112.09, a P/E/G ratio of 0.70 and a beta of 0.32. AbbVie Inc. has a 52 week low of $181.73 and a 52 week high of $244.81. The business’s 50 day moving average price is $211.05 and its 200-day moving average price is $219.07.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.59 by $0.06. The business had revenue of $15 billion for the quarter, compared to analysts’ expectations of $14.72 billion. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The firm’s quarterly revenue was up 12.4% on a year-over-year basis. During the same period in the prior year, the firm posted $2.46 EPS. On average, equities analysts anticipate that AbbVie Inc. will post 14.3 EPS for the current year.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie said nine-year CLL14 data showed venetoclax plus obinutuzumab delivered durable progression-free survival in previously untreated chronic lymphocytic leukemia, strengthening the case for the drug’s long-term commercial value. AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results
• Positive Sentiment: Investors are also focused on AbbVie’s broader pipeline and franchise strength, with commentary pointing to Skyrizi and Rinvoq continuing to drive revenue growth, which supports the company’s outlook beyond legacy Humira. Will Skyrizi & Rinvoq Continue to Drive AbbVie’s Topline Through 2026?
• Neutral Sentiment: Several market commentaries described AbbVie as a defensive, high-quality compounder, but noted the shares may not be cheap at current levels, which suggests valuation may temper upside even with strong fundamentals. AbbVie: A Defensive Compounder Worth Holding, But Not A Bargain Buy
• Negative Sentiment: One article highlighted regulatory risk around AbbVie’s fast-acting neurotoxin TrenibotE after an FDA complete response letter, which could delay a potential growth driver if development setbacks persist. FDA Issues Complete Response Letter for AbbVie’s Fast-Acting Neurotoxin TrenibotE; Spokane dermatologist Dr. Philip Werschler on What the Letter Means

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.